REMARKS/ ARGUMENTS

Currently Claims 1-25 are pending. Claims 1, 3, and 24 have been amended to correct typographical errors. Specifically, Claim 1 has been amended to replace the comma in line 2 with a semi-colon, Claim 3 has been amended to insert the recitation --in-- at line 2, and Claim 24 has been amended to replace the recitation "chamber" with the recitation --valve-- at line 1. Claims 21 and 22 have been amended such that they each now depend from Claim 16.

The Office Action states that Applicant is required to elect a single species from the following species, to which the claims shall be restricted if no generic claim is finally held to be allowable.

Species I - Figures 1, 2, 9, and 13;

Species II - Figure 3;

Species III - Figure 4;

Species IV - Figures 5a and 5b;

Species V - Figures 6, 7, 10, 11, and 14; and

Species VI - Figure 12;

with Figures 8a-d and 15 being generic to all species.

In response to this election of species requirement, Applicants hereby elect Species I for prosecution. Claims 1-8, 16, 17, and 21-25 are readable on the elected species.

Applicants understand that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141.

The concerns of the Examiner addressed in full, Applicants respectfully request the examination of the present application and the issuance of a Notice of Allowance forthwith. Applicants encourage the Examiner to direct any questions regarding this application to the undersigned, who may be contacted at (919) 483-9024.

Respectfully submitted:

J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115

Date: August 20, 2003
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

6